Alectinib

Drug Profile

Alectinib

Alternative Names: AF-802; Alecensa; ALECENSARO; Alectinib hydrochloride; CH-5424802; RG-7853; RO-5424802; RO-5452802

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Roche; University College London
  • Class Antineoplastics; Carbazoles; Morpholines; Nitriles; Phenyl ethers; Piperidines; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase I/II Thyroid cancer

Most Recent Events

  • 03 Aug 2017 The FDA will make a decision on sNDA approval in ALK-positive Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease) by November 30, 2017
  • 03 Aug 2017 The US FDA accepts a supplemental New Drug Application for ALK-positive Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease)
  • 03 Aug 2017 The US FDA grants Priority Review for alectinib in ALK-positive Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top